Boston Scientific Co. (NYSE:BSX) SVP Jeffrey B. Mirviss sold 33,512 shares of Boston Scientific stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $34.00, for a total value of $1,139,408.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Jeffrey B. Mirviss also recently made the following trade(s):
- On Thursday, June 14th, Jeffrey B. Mirviss sold 19,323 shares of Boston Scientific stock. The shares were sold at an average price of $32.64, for a total value of $630,702.72.
Shares of Boston Scientific stock traded down $0.22 during trading hours on Wednesday, hitting $33.34. The company’s stock had a trading volume of 4,035,350 shares, compared to its average volume of 7,994,418. Boston Scientific Co. has a 12-month low of $24.54 and a 12-month high of $37.30. The company has a market capitalization of $46.62 billion, a price-to-earnings ratio of 26.52, a PEG ratio of 2.46 and a beta of 0.76. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 0.68.
Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.01. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm had revenue of $2.38 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the previous year, the firm posted $0.29 earnings per share. The business’s revenue was up 10.1% compared to the same quarter last year. equities analysts expect that Boston Scientific Co. will post 1.39 earnings per share for the current year.
Several hedge funds have recently modified their holdings of BSX. BlackRock Inc. increased its holdings in shares of Boston Scientific by 8.7% in the first quarter. BlackRock Inc. now owns 106,292,471 shares of the medical equipment provider’s stock worth $2,903,912,000 after purchasing an additional 8,510,783 shares during the last quarter. Eaton Vance Management increased its holdings in shares of Boston Scientific by 42.3% in the first quarter. Eaton Vance Management now owns 6,564,617 shares of the medical equipment provider’s stock worth $179,345,000 after purchasing an additional 1,951,777 shares during the last quarter. Cannell Peter B & Co. Inc. bought a new stake in shares of Boston Scientific in the first quarter worth about $33,890,000. Bodenholm Capital AB bought a new stake in shares of Boston Scientific in the first quarter worth about $32,975,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Boston Scientific in the first quarter worth about $30,011,000. 89.12% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently weighed in on the company. ValuEngine upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Monday, June 11th. BMO Capital Markets lifted their target price on Boston Scientific to $36.00 and gave the company an “outperform” rating in a research report on Tuesday. Needham & Company LLC reiterated a “strong-buy” rating on shares of Boston Scientific in a research report on Friday, July 6th. Sanford C. Bernstein started coverage on Boston Scientific in a research report on Wednesday, June 27th. They set an “outperform” rating and a $38.00 target price on the stock. Finally, Argus boosted their price objective on Boston Scientific from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.87.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.